Literature DB >> 2368449

Thyroid carcinoma in Graves' disease.

O Ozaki1, K Ito, K Kobayashi, K Toshima, H Iwasaki, T Yashiro.   

Abstract

The pathogenesis of thyroid carcinoma in Graves' goiter is still obscure and the methods for preoperative diagnosis of such carcinomas is not well established. We studied the incidence, clinical features, and pathological findings of thyroid carcinoma in Graves' goiter. From October, 1983 to September, 1985, a total of 739 patients with Graves' disease underwent subtotal thyroidectomy at Ito Hospital, Tokyo. All of these patients underwent roentgenography of the neck before surgery. Thyroid carcinoma was revealed in the resected specimen in 15 (2.0%) of 739 patients. During the same period, another 4 patients underwent surgery for thyroid carcinoma who had had Graves' disease previously and these 4 cases were included in the present study. The incidence of thyroid carcinoma associated with Graves' disease was 2.6% (19 of 743 cases). Histological examination revealed 15 papillary and 4 follicular carcinomas. The size of the carcinoma foci was 13.8 +/- 15.6 mm in diameter (range: 1-60 mm), 10 (52.6%) foci being 10 mm or greater. Invasive growth into the surrounding thyroid tissue was predominant and regional lymph node metastasis was noted in all 6 patients who underwent cervical dissection. Preoperative roentgenography revealed calcification in 5 (26.3%) of 19 cases. Our present study indicates that thyroid carcinoma in Graves' goiter may show markedly invasive growth with lymph node metastasis even though the primary tumor is small in size, and it is suggested that the detection of calcification may serve as a part of the diagnostic measures when the carcinoma focus is difficult to palpate in the diffusely-enlarged Graves' goiter.

Entities:  

Mesh:

Year:  1990        PMID: 2368449     DOI: 10.1007/bf01658550

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  8 in total

1.  Carcinoma of the thyroid occurring in a diffuse toxic goiter.

Authors:  E W KONEMAN; K C SAWYER
Journal:  Am J Surg       Date:  1961-02       Impact factor: 2.565

2.  Nodular goiter and malignant lesions of the thyroid gland.

Authors:  O H BEAHRS; J de J PEMBERTON; B M BLACK
Journal:  J Clin Endocrinol Metab       Date:  1951-10       Impact factor: 5.958

3.  Thyroid carcinoma in thyrotoxic patients treated by surgery.

Authors:  F Pacini; R Elisei; G C Di Coscio; S Anelli; E Macchia; R Concetti; P Miccoli; M Arganini; A Pinchera
Journal:  J Endocrinol Invest       Date:  1988-02       Impact factor: 4.256

4.  Hyperthyroidism and thyroid cancer.

Authors:  C J Edmonds; M Tellez
Journal:  Clin Endocrinol (Oxf)       Date:  1988-02       Impact factor: 3.478

5.  Incidence of thyroid carcinoma in Graves' disease.

Authors:  S J Shapiro; N B Friedman; S L Perzik; B Catz
Journal:  Cancer       Date:  1970-12       Impact factor: 6.860

6.  Coexistence of hyperthyroidism and thyroid cancer.

Authors:  R A Wahl; P Goretzki; H Meybier; J Nitschke; M Linder; H D Röher
Journal:  World J Surg       Date:  1982-07       Impact factor: 3.352

7.  Thyroid carcinoma in Graves' disease.

Authors:  L M Farbota; D B Calandra; A M Lawrence; E Paloyan
Journal:  Surgery       Date:  1985-12       Impact factor: 3.982

8.  Graves' disease and thyroid cancer.

Authors:  R Behar; M Arganini; T C Wu; M McCormick; F H Straus; L J DeGroot; E L Kaplan
Journal:  Surgery       Date:  1986-12       Impact factor: 3.982

  8 in total
  24 in total

Review 1.  Recurrent or persistent thyroid cancer of follicular cell origin.

Authors:  M Duren; Q Y Duh; A E Siperstein; O H Clark
Journal:  Curr Treat Options Oncol       Date:  2000-10

2.  Thyroid cancer in hyperthyroidism: incidence rates and value of ultrasound-guided fine-needle aspiration biopsy in this patient group.

Authors:  M Sahin; N D Guvener; F Ozer; A Sengul; D Ertugrul; N B Tutuncu
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

3.  Thyroid carcinoma in patients with Graves' disease: an institutional experience.

Authors:  Shuanzeng Wei; Zubair W Baloch; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

4.  Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis?

Authors:  D G P N Villagelin; R B Santos; J H Romaldini
Journal:  J Endocrinol Invest       Date:  2011-07-13       Impact factor: 4.256

5.  Aggressive behavior of papillary microcarcinoma in a patient with Graves' disease initially presenting as cystic neck mass.

Authors:  M Braga; H Graf; A Ogata; J Batista; Neto C A Hakim
Journal:  J Endocrinol Invest       Date:  2002-03       Impact factor: 4.256

6.  Aberrations of growth factor control in metastatic follicular thyroid cancer in vitro.

Authors:  T Hoelting; A Zielke; A E Siperstein; O H Clark; Q Y Duh
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

7.  Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features.

Authors:  Kyung-Eun Kim; Eun-Kyung Kim; Jung Hyun Yoon; Kyung Hwa Han; Hee Jung Moon; Jin Young Kwak
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

8.  Thyroid carcinoma after radioactive iodine therapy for Graves' disease.

Authors:  O Ozaki; K Ito; T Mimura; K Sugino; Y Kitamura; H Iwabuchi; M Kawano
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

9.  Predictive factors of thyroid cancer in patients with Graves' disease.

Authors:  Meng Ren; Mu Chao Wu; Chang Zhen Shang; Xiao Yi Wang; Jing Lu Zhang; Hua Cheng; Ming Tong Xu; Li Yan
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

10.  Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications.

Authors:  P E Goretzki; J Lyons; S Stacy-Phipps; W Rosenau; M Demeure; O H Clark; F McCormick; H D Röher; H R Bourne
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.